Antifracture efficacy of antiresorptive agents are related to changes in bone density

Journal of Clinical Endocrinology and Metabolism

Volumn 85, Issue 1, 2000, Pages 231-236

  Wasnich, Richard D ^a   Miller, Paul D ^b  

^a Hawaii Osteoporosis Center   (United States)

^b University of Colorado Health Sciences Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; CALCITONIN; ETIDRONIC ACID; RALOXIFENE; TILUDRONIC ACID;

ARTICLE; BONE DENSITY; BONE MASS; BONE STRENGTH; BONE STRESS; CLINICAL TRIAL; DRUG EFFICACY; HORMONE SUBSTITUTION; HUMAN; IN VITRO STUDY; MECHANICAL STRESS; OSSIFICATION; OSTEOLYSIS; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; TREATMENT OUTCOME; VERTEBRA FRACTURE;

EID: 0034456357     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jcem.85.1.6267     Document Type: Article

References (38)

1. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures
2. How hip and whole body bone mineral density predict hip fracture in elderly women. The EPIDOS prospective study
3. Changes in BMD substantially underestimate the anti-fracture effects of alendronate and other antiresorptive drugs
4. Prevention of fails-related fractures: Vitamin D reduces body sway in the elderly - A prospective, randomized, double blind study
5. Therapy of osteoporosis: Calcium, vitamin D, and exercise
6. The effect of 2 and 3 years of raloxifene on vertebral and non-vertebral fractures in postmenopausal women with osteoporosis
7. Salmon calcitonin nasal spray (NS-CT) reduces risk of vertebral fracture(s) in established osteoporosis and has continuous efficacy with prolonged treatment: Accrued 5 year worldwide data of the PROOF study
8. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis
9. Chronic intermittent cyclical administration of tiludronate in postmenopausal osteoporosis: Report of two multicenter studies in 2316 patients
10. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures
11. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: Results from the Fracture Intervention Trial
12. The prediction of fracture risk with densitometry
13. Design of the Fracture Intervention Trial
14. Treatment of established postmenopausal osteoporosis with raloxifene: A randomized trial
15. Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis: A dose-response study
16. Dose-response relationships for alendronate treatment in osteoporotic elderly women
17. Biomechanics of fractures
18. Assessment of the strength of proximal femur in vitro: Relationship to femoral bone mineral density and femoral geometry
19. Biomechanics of age-related fractures
20. Determinants of skeletal mass and strength
21. Bisphosphonate effects and the bone remodeling transient
22. Bone mass homeostasis and bisphosphonate action
23. Trabecular thickening may compensate for reduced connectivity in human trabecular bone
24. Cyclical etidronate in the treatment of postmenopausal osteoporosis: Efficacy and safety after seven years of treatment
25. The effects of oral alendronate on bone mass and turnover and safety: Five-year treatment of osteoporosis in postmenopausal women
26. Early estrogen replacement therapy reverses the rapid loss of trabecular bone volume and prevents further deterioration of connectivity in the rat
27. Bone age, mineral density, and fatigue damage
28. Bone mineral density reflects bone mass but also the degree of mineralization of bone: Therapeutic implications
29. The effects of 2-year treatment with the aminobisphosphonate alendronate on bone metabolism, bone histomorphometry, and bone strength in ovariectomized nonhuman primates
30. Systemic underestimation of association between serum cholesterol concentration and ischaemic heart disease in observational studies: Data from the BUPA study
31. Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study
32. Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis
33. Comparison of alendronate and sodium fluoride effects on cancellous and cortical bone in minipigs
34. Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis
35. Fluoride salts are no better at preventing new vertebral fractures than calcium-vitamin D in postmenopausal osteoporosis: The FAVOS study
36. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis
37. Treatment of postmenopausal osteoporosis with transdermal estrogen
38. Alendronate increases the mechanical loading response and prevents bone loss